BIT's 15th Annual Congress of International Drug Discovery Science and Technology - Japan 2017 (IDDST-Japan 2017)
★ Scientific Program

BIT's 15th Annual Congress of

International Drug Discovery Science and Technology - Japan 2017

Theme: Dedicated to Accelerating Drug Innovation

Time: July 25-27, 2017

Venue: Osaka, Japan

 

Keynote Forum Scientific Program
Section 1 Section 2 Section 3 Section 4 Section 5 Section 6 Young Scientist Forum

 

Section 2: Medicinal Discovery Chemistry & Drug Design
Session 201: Novel Drug Targets and Biomarker
Day 1: Afternoon, Tuesday, July 25, 2017
13:30-18:20
Place: Yume, 2F, Banquet Tower, HRO
Chair: Dr. Branko Stefanovic, Professor, Florida State University, USA
Time FaceOn Speeches and Speakers Org. Logo
13:00-13:05 Chair's Introduction
13:05-13:30 Title: Bi-Specific Antibodies: Discovery and Engineering
Dr. John Delaney,
Executive Director, Amgen Inc., USA
 
13:30-13:55 Title: Novel Target for Development of Specific Antifibrotic Drugs: Validation and High Throughput Screening Methods
Dr. Branko Stefanovic,
Professor, Florida State University, USA
13:55-14:20 Title: Calcium Sensing Receptor, A Singular and Complex Therapeutic Target
Dr. Michel Brazier,
Tenured Professor, Jules Verne University of Picardie, France
14:20-14:45 Title: Structure, Mechanism of Action, and Inhibition of Peptidoglycan O-acetyltransferase A (OatA), An Anti-virulence Target of Gram-positive Pathogens
Dr. Anthony J. Clarke,
Professor, University of Guelph, Canada
14:45-15:10 Title: LKB1 is a New Target for Ageing Related Diseases
Dr. Yasuo Ido,
Associate Professor, Boston University School of Medicine, USA
15:10-15:25 Coffee Break
15:25-15:50 Title: Novel Stool Biomarkers for Colorectal Cancer
Dr. Jun Yu,
Director, Research Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
15:50-16:15 Title: Platelets as Drug Targets in Sepsis
Dr. Dermot Cox,
Associate Professor, Royal College of Surgeons in Ireland, Ireland
16:15-16:40
Title: Two New Monoclonal Anti-glypican-3 Antibodies for Hepatocellular Carcinoma Cell Targeted-Drug Development
Dr. Preeyanat Vongchan,
Associate Dean, Chiang Mai University, Thailand
16:40-17:05   Title: The Role of Kidney Injury Molecule-1, Interleukin-18 and Glutathione-S-transferase-π in Paediatric HIVAN
Dr. Rajendra Bhimma,
Associate Professor, University of KwaZulu-Natal, South Africa
 
17:05-17:30 Title: Computer Based Identification of Possible Molecular Targets for Induction of Drug Resistance Reversion in Multidrug Resistant Mycobacterium Tuberculosis
Dr. Oleg N. Reva,
Associate Professor, University of Pretoria, South Africa
17:30-17:55 Title: 5-methoxytryptophan as an Innate Vasoprotective and Anti-inflammatory Molecule
Dr. Cheng-Chin Kuo,
Associate Investigator, National Health Research Institutes, Taiwan
17:55-18:20 Title: Clec14a as a Novel Therapeutic Target in Angiogenesis: A New Challenge with Antibody-based Targeting of VEGF
Dr. Sukmook Lee,
Principal Investigator, Scripps Korea Antibody Institute, South Korea

 

Session 202: Drug Design and Synthesis (Part I) - Agonists and Inhibitors
Day 2: Morning, Wednesday, July 26, 2017
08:30-12:10 
Place: Yume, 2F, Banquet Tower, HRO
Chair: Dr. Youla S. Tsantrizos, Professor, McGill University, Canada
Time FaceOn Speeches and Speakers Org. Logo
08:30-08:35 Chair's Introduction
08:35-09:00 Title: Design and Synthesis of Highly Selective 5-HT2C Receptor Agonists as Potential Novel Treatment for Neuropsychiatric Diseases
Dr. Andreas Haupt,
Associate Director & Group Leader, Neuroscience Discovery, AbbVie Deutschland GmbH & Co. KG, Germany
09:00-09:25 Title: PPI-Focused Library of Macrocyclic β-Peptidomimetic Lactams: Design and Synthesis
Dr. Volodymyr Kysil,
Director of Chemistry, ChemDiv, Inc., USA
09:25-09:50 Title: Sulfoximines from a Medicinal Chemist’s Perspective: Physicochemical and in vitro Properties Relevant for Drug Discovery
Dr. Christian Gnamm,
Research Scientist, Boehringer Ingelheim Pharma GmbH Co. KG, Germany
09:50-10:15 Title: Phosphorus-containing Compounds as Bioisosteres of Isoprenoids: Their Role in Cell Death and Drug Discovery
Dr. Youla S. Tsantrizos,
Professor, McGill University, Canada
10:15-10:30 Coffee Break
10:30-10:55 Title: Discovery of GLPG1690: A First-in-class Autotaxin Inhibitor in Clinical Development for the Treatment of Idiopathic Pulmonary Fibrosis
Dr. Oscar Mammoliti,
Team Leader, Galapagos NV, Belgium
10:55-11:20 Title: The Calcium Leak from Endoplasmic Reticulum as a New Pharmacological Target in Cancer Therapy
Dr. Adolfo Cavalie,
Professor, Department of Experimental and Clinical Pharmacology and Toxicology, Saarland University, Germany
11:20-11:45 http://www.dnaday.com/images/psp/no.jpg Title: GSK-3b Inhibitors for Alzheimer’s Disease
Dr. Kazutoshi Watanabe,
Principal Research Scientist, Mitsubishi Tanabe Pharma Corporation, Japan
11:45-12:10 Title: Neurotoxic Effects of Secretable Products from of Human T-cell Leukemia Virus Type 1-Infected Lymphocytes. Betamethasone Treatment of Patients with Spastic Paraparesis
Dr. Maria A. Valenzuela,
Professor, University of Chile, Chile

 

Session 202: Drug Design and Synthesis (Part II) - Structure-Based Drug Design
Day 2: Afternoon, Wednesday, July 26, 2017
13:00-17:55 
Place: Yume, 2F, Banquet Tower, HRO
Chair: Dr. Jorg Benningshof, Director, Parallel Chemistry Group, Mercachem, The Netherlands
Co-Chair: Dr. Patrick Y. S. Lam, Adjunct Professor, Drexel University College of Medicine, USA
Time FaceOn Speeches and Speakers Org. Logo
13:00-13:05 Chair's Introduction
13:05-13:30 Title: Privileged Structures: A Versatile Concept to Explore New Chemical Space with Medicinal Chemistry Utility
Dr. Jorg Benningshof,
Director, Parallel Chemistry Group, Mercachem, The Netherlands
13:30-13:55 Title: Design of Multivalent Peptide and Peptidomimetic Ligands for the Treatment of Disease Which are Bioavailable and Lack Toxicities
Dr. Victor J. Hruby,
Regents Professor, University of Arizona, USA
13:55-14:20 Title: First Successful Use of Halogen Bonding in Structure-based Drug Design to Generate a Novel Factor Xa Inhibitor
Dr. Patrick Y. S. Lam,
Adjunct Professor, Drexel University College of Medicine, USA
14:20-14:45 Title: Fragment Hits - What are They?
Dr. Fabrizio Giordanetto,
Head Medicinal Chemistry, D. E. Shaw Research LLC, USA
14:45-15:10 Title: Discovery of GDC-0068 (Ipatasertib), A Selective ATP-competitive AKT Inhibitor for the Treatment of Human Tumors
Dr. Bing-Yan Zhu,
Medicinal Chemist, Genentech, Inc., USA
15:10-15:25 Coffee Break
15:25-15:50 Title: Expression Profile Based Drug Design and Personalized Medicine
Dr. Thurai Moorthy,
President, MultiGEN Diagnostics, USA
15:50-16:15 Title: A New Druggable Site to Rescue p53 Folding and Activity
Dr. John Karanicolas,
Associate Professor, Fox Chase Cancer Center, USA
16:15-16:40 Title: Fluorinated Benzamides: Molecular Docking and Pharmacophore Modeling Studies Targeting CETP Inhibition
Dr. Reema Abu Khalaf,
Associate Professor, Al-Zaytoonah University of Jordan, Jordan
16:40-17:05 Title: A New INH Derivative More Active Than INH against Resistant Strains of Mycobacterium Tuberculosis: QSARs, Molecular Dynamic Simulations and Kinetic Studies
Dr. Filomena Martins,
Assistant Professor, University of Lisbon, Portugal
17:05-17:30 Title: Designing a Novel Series of p110α-Selective Phosphoinositide 3-Kinase Inhibitors: A Scaffold Hopping Approach
Dr. Jackie D. Kendall,
Senior Research Fellow, Auckland Cancer Society Research Centre, University of Auckland, New Zealand
17:30-17:55 Title: Phenalenyl Based Pt(II) Compounds and Liposomal Formulations as Potential Anticancer Drugs
Dr. Arindam Sarkar,
Principal Scientist (Chemistry), Invictus Oncology Pvt. Ltd., India

 

Session 203: Lead Optimization Strategies
Day 3: Morning, Thursday, July 27, 2017
08:30-10:40 
Place: Yume, 2F, Banquet Tower, HRO
Chair: Dr. Glenn J. Myatt, Chief Scientific Officer, Leadscope, Inc., USA
Time FaceOn Speeches and Speakers Org. Logo
08:30-08:35 Chair's Introduction
08:35-09:00 Title: Extending Public (Q)SARs to Incorporate Proprietary Knowledge
Dr. Glenn J. Myatt,
Chief Scientific Officer, Leadscope, Inc., USA
 
09:00-09:25 Title: Smart Lead Optimization: Novel Approaches to the Selection of Higher Quality Clinical Candidates
Dr. Luca F Raveglia,
Head, Medicinal Chemistry, Drug Design & Discovery, Aptuit, Italy
09:25-09:50 Title: D-seco-Vitamin D Analogs: Synthesis and Biological Activity
Dr. Rafal R. Sicinski,
Associate Dean, Faculty of Chemistry, University of Warsaw, Poland
09:50-10:15 Title: Evolutionary Inference for Lead Optimization
Dr. Irene Poli,
Professor, Ca' Foscari University, Italy
10:15-10:40 Title: Virtual Screening for Novel Atg5-Atg16 Complex Inhibitors for Autophagy Modulation
Dr. Johannes Reynisson,
Senior Lecturer, University of Auckland, New Zealand

 

Session 204: Small Molecule Drug for Major Diseases
Day 3: Afternoon, Thursday, July 27, 2017
13:00-17:05 
Place: Yume, 2F, Banquet Tower, HRO
Chair: Dr. Helmut Thomas, President and CEO, Cyclenium Pharma Inc., Canada
Time FaceOn Speeches and Speakers Org. Logo
13:00-13:05 Chair's Introduction
13:05-13:30 Title: SAR156497 an Exquisitely Selective Inhibitor of Aurora Kinases
Dr. Jean-Christophe Carry,
Group Leader, Medicinal Chemistry, Sanofi, France
13:30-13:55 Title: Drug Discovery with Small-molecule CMRT™ Macrocycles – Design and Experience
Dr. Helmut Thomas,
President and CEO, Cyclenium Pharma Inc., Canada
13:55-14:20 Title: Imidazolines – Omnipotent Small Molecules in Drug Design
Dr. Franciszek Saczewski, 
Head, Department of Chemical Technology of Drugs, Faculty of Pharmacy, Medical University of Gdansk, Poland
14:20-14:45

Title: Discovery of Finerenone - A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Dr. Lars Baerfacker,
Principal Scientist, Bayer Pharma, Germany

14:45-15:10 Title: Phenotypic Screening Revealed Monoamine Receptors as Potential Drug Targets for the Treatment of Myeloproliferative Neoplasms
Dr. Meng Ling Choong,
Group Leader, Experimental Therapeutics Centre, A*STAR, Singapore
15:10-15:25 Coffee Break
15:25-15:50 Title: Dihydropyrimidone-derivated Selenoesters and Selenoureas as Promising Molecules for Tumor Control
Dr. Rozangela C. Pedrosa,
Professor, Federal University of Santa Catarina, Brazil
15:50-16:15 Title: Purine-type Compounds Induce Microtubule Fragmentation and Lung Cancer Cell Death through Interaction with Katanin
Dr. Szu-Hua Pan,
Assistant Professor, National Taiwan University, Taiwan
16:15-16:40 Title: Reprofiling of Phosphonated Isoxazolidine Nucleosides towards Antiproliferative Activity: Synthesis, Antiproliferative Activity and Computational Study
Dr. Majdi M. Bkhaitan,
Assistant Professor, Umm Al-Qura University, Saudi Arabia
 
16:40-17:05 Title: Chronic Myelogenous Leukemia – Combating T315I Mutation
Dr. Amala Kompella,
General Manager, Natco Pharma Limited, India

 

Hosting Organization
whtslogo.JPG
World High Technology Society
Operating Organization
BIT Group Global Ltd.
Supporting Organizations

Keio University School of Medicine, Japan

Nagoya University Graduate School of Pharmaceutical Sciences, Japan

Shenzhen International Institute for Biomedical Research, China

Official Travel Agency
Media Partners

Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2016-2017 BIT Group Global Ltd.